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S_ry Factors involved in the control of the biological properties of gliomas, the major form of brain
tumour in man, are poorly documented. We investigated the role of transforming growth factorP, (TGF-P,) in
the control of proliferation of human glioma cell lnes as well as normal human fetal brain cells. The data
presented show that TGF-, exerts a growth-inhibitory action on both human fetal brain cells and three cell
lines derived from human glioma of different grades of malignancy. In addition, this growth-inhibitory effect is
dose dependent and serum independenL Since TGF-4 is known to be involved in the control of cell migration
during ontogenesis and oncogenesis, we investigated the role of this factor in the motile and invasive
behaviour that characterises human gliomas in vivo. TGF-4, was found to elicit a strong stimulation of
migration and invasiveness of glioma cells in vitro. In combination with recent data showing an inverse
correlation between TGF-Al expression in human gliomas and survival, these findings may suggest that
TGF-P, plays an important role in the malignant progression of gliomas in man. A study of the molecular
mechanisms involved in the antiproliferative action and the invasion-promoting action ofTGF-Al may help to
identify new targets in therapy for brain tumours. A combined antiproliferative and anti-invasive therapy
could be envisaged.
Gliomas represent the major form of intrinsic brain tumour
in man (Russell & Rubinstein, 1989). The most significant
biological feature of these tumours is their local invasive
infiltration of normal tissue, irrespective of their histological
grade ofmalignancy. Even low-grade tumours may be poorly
demarcated and are hardly ever properly encapsulated; con-
sequently, their complete surgical removal is difficult, if not
impossible. Not surprisingly, they frequently recur and
therefore carry a poor prognosis. The factors and
mechanisms involved in this invasive behaviour as well as in
the control of glioma cell proliferation are poorly
documented.
Transforming growth factor PI (TGF-i1) is a member of a
large family of structurally related proteins which play a role
in the control of proliferation, differentiation and mor-
phogenesis in cultured cells and organisms from insects to
mammals (reviewed in Massague, 1990). TGF-P, was initially
defined by its ability to induce anchorage-independent
growth of non-transformed rat kidney cells (Roberts et al.,
1981). However, different effects ofTGF-PI have been subse-
quently reported in a large variety of cells. It is now well
established that TGF-PI is antimitogenic in most cell types.
Its strong inhibitory action has been demonstrated on
various cell types, including both normal and transformed
epithelial, endothelial, fibroblast, lymphoid and haemato-
poietic cells. In addition, TGF-P has been shown to stimulate
extracellular matrix formation and thereby modulate cell
adhesion and migration (Massague, 1990). In spite of the
considerable number of studies aimed at elucidating the
action of TGF-P, in various tissues, little is known about its
role in the central nervous system (CNS). It has been recently
demonstrated that TGF-PI exerts an inhibitory effect on the
proliferation of normal rat astroglial cells in culture
(Labourdette et al., 1990; Lindholm et al., 1992). It has also
been reported that TGF-P, plays a role in the control of
differentiation of normal astrocytes in the developing and
adult mouse (Sakai et al., 1990). We have therefore studied
the action of TGF-P, on proliferation of neoplastic and
normal human glia, cells which represent 50% of the brain's
volume and play vital roles in the developing and adult CNS.
We have also investigated the role ofTGF-P1 in the charac-
teristic motile and invasive behaviour of human glioma cells
since this factor is known to play a central role in the control
of cell adhesion and migration during ontogenesis and
oncogenesis (Massague, 1990).
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Materials and mthod
Cell culture
The IPNT-H cell line was derived from a pilocytic astro-
cytoma of the hypothalamus in a 6-month-old child. Despite
the fact that the tumour from which this cell line was derived
was histologically classified as a pilocytic astrocytoma, it
showed a high proliferative rate in agreement with recent
reports demonstrating that occasionally these tumours pos-
sess a high mitotic index (Ito et al., 1992). Histological
analysis showed the presence of mitoses in one-tenth of
high-power fields, but no necrosis or endothelial cell pro-
liferation was noted. In some areas there was an increase in
cellularity and very occasional entrapped neurons could be
discerned within the tumour. IPNT-H cells were used at
passage 7; IPSB-18 was derived from a human grade 3
tumour of the temporal lobe in a 48-year-old man (Knott et
al., 1990) and used at passage 32; and IPRM-5 was derived
from a glioblastoma multiforme of the frontal lobe in a
49-year-old woman and used at passage 15. Fetal brain cells
were derived from the left hemisphere of a 16-week-gestation
human fetus.
Cells were routinely propagated in culture in a standard
humidified incubator at 37C in a 5% carbon dioxide/95%
air atmosphere. Plastic tissue culture dishes were obtained
from Marathon LS (London, UK). Cells were grown in
Dulbecco's modified Eagle medium (DMEM) supplemented
with 10% heat-inactivated fetal calf serum (FCS) (Gibco
BRL, Middlesex, UK) and a 1% antibiotic/antimycotic solu-
tion at a final concentration of 100 IU of pencillin, 100 Lg of
streptomycin and 0.25 Lg of amphotericin per ml (Gibco
BRL). For TGF-P, treatment, cells were plated in DMEM
containing 10% FCS for 24 h. The medium was then
replaced by DMEM supplemented with 2% FCS and con-
taining TGF-4, at the indicated concentrations. Recombinant
TGF-P, (Gibco BRL) was dissolved in 50 mM sodium
acetate, pH 4.5, containing 1% bovine serum albumin (BSA)
and reconstituted with DMEM containing 1% BSA.
Cellproliferation assay
Cells were plated at 5 x I04 cells per well in six-well culture
plates in DMEM containing FCS in the absence or presence
of 5 ng ml-' TGF-,B. The medium was changed once, after 3
days of incubation, and the cell number was determined,
after 7 days, by trypinisation and counting in a haemo-
cytometer. All experiments were performed in triplicate and
repeated at least twice.
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Motility assay
Cell motility was monitored by a chemotaxis assay. Twenty-
four-well transwell units incorporating 8pm polycarbonate
filters (Costar, Cambridge, UK) were used. Each lower com-
partment of the transwell contained 500 tlI of the chemoat-
tractant solution containing lOng ml' platelet-derived
growth factor (PDGF) (Gibco BRL) dissolved in DMEM.
Cells were incubated for 48 h in the presence or absence of
TGF-Al in 2% FCS-containing medium. Cells were then
harvested by trypsinisation and counted, and 5 x 103 cells
were resuspended in 100 tl of their original medium and
placed in the upper compartment of the transwell unit. After
18 h of incubation at 3TC in a humidified 95% air/5%
carbon dioxide atmosphere, cells were fixed with acetic acid/
alcohol and stained with Giemsa. Cells on the upper surface
of the filter were removed by wiping with a cotton swab, and
motility was detrmined by counting the cells that had
migrated to the lower side of the filter with a phase-contrast
microscope at 200xmagnification. Thirteen fields were
counted for each assay. Each sample was assayed in trip-
lcate, and assays were repeated twice.
Invasion assay
In vitro invasiveness was measured by the method of Albini
et al. (1987) with modifications. For the motility assays we
used 24-well transwell units with 8-pm-porosity polycar-
bonate filters but coated with the reconstituted basement
membrane substance, Matrigel (Collaborative Research, Lex-
ington, MA, USA). The filters in the transwells were coated
with 20 tg of Matrigel per filter in cold DMEM to form a
thin, continuous layer on top of the filter. Matrigel was left
to air dry overnight. Prior to addition of the cells, exess
medium was removed from the upper compartment. The
lower compartment contained 0.5 ml of serum-free medium
supplemented with PDGF (10 ngml-') as a chemoattractant.
Cells were incubated for 48 h in the presence or absence of
TGF-Al in 2% FCS-containing medium. Cells were then
harvested by trypsnisation and counted, and 5 x 103 cells
were resuspended in 100 sl of their original medium and
placed in the upper compartment of the transwell unit for
18 h at 37C in a humidified 95% air/5% carbon dioxide
atmosphere. After incubation, the filters were treated and the
cells counted as described above for the motility assay. All
the assays were carried out in triplicate, and the assay
repeated twice.
The standard deviations were typically less than 10% in
individual experiments and thus are not presented.
Results
Growth-inhibitory effect ofTGF-P, on glial cells
The effect of TGF-0, on the growth of three human glioma-
derived cell tines, IPNT-H, IPSB-18 and IPRM-5, and on
human fetal brain cells (Figure la) was assd. TGF-P,
inhibited the proliferation of human fetal brain cells by 45%.
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Fugwe I Growth-inhibitory effect of TGF-^ on fetal brain cells (FBCs) and the three glioma cell lines. a, Proliferation assay as
described in Materials and methods. *, Control; 0, + TGF-P. b, The IPNT-H cells were plated at 40 x 10i cells per well in the
absence (0) or presence (-) of 5ng ml- TGF-pl. The cells were also incubated with 5ng ml-' TGF-, for 24h and then the
medium repla with fresh medium without TGFA on day 0 (O). The cell number was determined, as in a every day after the
incubation. c, IPNT-H cells were incubated in the presence of increasing concentrations ofTGF-A and the medium changed every
day to ensure the peirmanent presence of fresh TGF-1. Cells were then counted after 7 days of incubation. d, Cells were treated as
in a but in the prsence of various concentrations of FCS. *, - TGF-P; 0, + TGF-P.
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The human glioblastoma cell line IPRM-5 was inhibited by
40%, while EPNT-H cells were inhibited by 32%, probably
because of its high proliferative rate. The grade 3 glioma cell
line, IPSB-18, which has the longest doubling time (36h),
was found to be most sensitive to the growth-inhibitory
action of TGF-Al (64% inhibition).
Furthermore, we have studied the time-course of the
inhibitory action of TGF-P, on the highly proliferative
IPNT-H cells. Figure lb shows a strong inhibitory effect of
TGF-01 on proliferation of IPNT-H, in a low concentration
of serum. A 33% inhibition was attained after only 1 day of
incubation with TGF-Al. This increased to about 50% at day
2, and reached 60% at day 3. IPNT-H cells were also
incubated in the presence of TGF-P, for 24 h, and then the
medium was replaced by medium without TGF-A,. Interest-
ingly, the same extent of inhibition was observed under these
conditions. This result suggests that 24 h is sufficient for
TGF-P, to trigger a prolonged growth-inhibitory signal into
the cells.
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TGF-P, grow th-inhibitory effect is dose dependent
We also studied the dose-response relationship for the
action of TGF-P1 on IPNT-H cells (Figure lc). A marked
inhibitory effect of approximately 70% was observed at
1 ng ml-' TGF-pl. At 2.5 ng mrl-' the cells were slightly more
inhibited than with 1 ng ml-' in low-serum conditions (2%
FCS). However, a dramatic inhibitory effect, of about 90%,
was obtained at 5 ng ml-1. Intriguingly, this concentration
was found to be more effective than 1Ong ml-'. The same
observation was made with 5% FCS-containing medium
(data not shown). At 20 ng ml-', the proliferation of IPNT-
H cells was completely stopped.
TGF-P, growth-inhibitory effect is serwn independent
TGF-B, has also been shown to be growth stimulatory
depending on cell type, culture conditions and the presence
of other mitogenic factors. For example, Massague (1984)
has shown that TGF-P, stimulates proliferation of AKR-2B
mouse fibroblasts in 'mitogen-poor' medium. We therefore
studied the effect of TGF-P1 on the IPNT-H cell line at
different concentrations of serum (Figure ld). TGF-P1 was
seen to exert a growth-inhibitory effect independent of the
concentration of FCS present. A 35% growth inhibition was
obtained in 20% serum concentration, a 37.5% inhibition in
10%, a 30% inhibition in 5%, a 50% inhibition in 2.5% and
a 30% inhibition in 1%. In serum-free medium (0%), the cell
number dropped from 8.8 x I0 cells per well to 2 x 104 cells
per well.
TGF-P, stimulates glioma cell migration in vitro
One of the most important biological hallmarks of gliomas is
their extensive local diffuse spread into the brain. The precise
mechanisms involved in this invasive behaviour are not fully
understood. Among the well-established biological roles of
TGF-P, is its stimulation of extracellular matrix (ECM) for-
mation (Massague, 1990). This action generally leads to an
up-regulation of cell adhesion and may therefore modify the
motile behaviour of cells. It was therefore important to study
the effect ofTGF-P, on glioma cell motility and invasiveness
in vitro. Eight-micron-porosity polycarbonate filters, in
modified Boyden chambers, were used to assess the effect of
TGF-P, on motility. PDGF was used in these studies as a
chemoattractant on the basal side of the filter since this
factor has already been shown to have a pronounced
chemotactic effect on astroglial cells in vitro (Bressler et al.,
1985). The highly malignant, glioblastoma-derived, cell line
IPRM-5 did not attach to the filter and was therefore unable
to migrate (Figure 2a). In contrast, the two other cell lines,
IPSB-18 and IPNT-H, were able to migrate to the lower side
of the filters, with IPSB-18 being three times more efficient
than IPNT-H. Interestingly, IPSB-18 and IPNT-H cells were
stimulated by TGF-P, to migrate seven and three times more
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efficiently respectively. In addition, IPRM-5 cells treated with
TGF-P, acquired a migratory potential similar to that of the
IPSB-18 cell line.
TGF-0, stimulates glioma cell invasiveness in vitro
For assessment ofinvasion, a modified version of the method
of Albini et al. (1987) was used incorporating the basement
membrane Matrigel, an extract of the Englebreth-Holm-
Swarm tumour. The three cell lines penetrated the matrix and
migrated to the lower side of the filter to different extents
(Figure 2b). IPNT-H cells were found to be more invasive
than IPRM-5 cells. It is worth noting that, clinically, the
IPNT-H tumour was very aggressive and proved rapidly
fatal. IPSB-18 cells were found to be less invasive than the
other two cell lines, despite showing the highest migratory
activity. This may suggest that IPRM-5 and EPNT-H cells
synthesise more of the proteinases that are necessary for the
degradation of ECM proteins in order to invade. In addition,
IPRM-5 cells, which proved to be non-migratory, showed
both motility and invasive activity once plated on Matrigel.
This observation suggests that IPRM-5 cells failed, under
these conditions, to secrete their own ECM proteins which
are necessary for attachment and subsequent migration, and
probably acquired the motile property because of the
presence of adhesion substrates in Matrigel. Interestingly,
TGF-4, did not affect IPNT-H invasiveness, while the
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Fugwe 3 Example of invading cells. a, IPRM-5 control cells; b,
TGF-A1-pretreated IPRM-5 cells. A higher number of invading
cells, able to degrade Matrigel and to migrate to the lower side of
the filter, can be appreciated in cls treated with TGF-A (b) in
comparison with the control (a).
invasiveness of IPSB-18 and IPRM-5 in Matrigel was in-
creased about 3-fold and 20-fold respectively (Figures 2 and
3). It is worth noting that migration of IPSB-18 cells was
much more stimulated than its invasion. This could be
explained by a stimulation, in these cells, of motility factors
or motility-promoting ECM proteins and by low levels of
proteinases able to degrade Matrigel.
To the best of our knowledge, the data presented in this
paper represent the first report on the action of TGF-Al on
proliferation of normal and transformed human glial cells, as
well as on the migratory and invasive properties of human
neoplastic glial cells in vitro. We demonstrate that TGF- is
a potent growth inhibitor of human fetal brain cells and
glioma-denved cell lines in ntro. Preliminary experiments
were carried out after 30min and 1 and 2h of incubation
with TGF-P1 to see whether this effect is due to an early cell
response. These short incubations had no effect on cell
growth (data not shown). Combined with the data presented
in Figure lb, this observation suggests that the permanent
pesence of TGF-, is probably required for a cooperation
with products of late-responsive genes in order to slow cell
proliferation. The growth responsiveness of fetal brain cells
to TGF-1, suggests that this factor may play a role in the
development of these cells. This is substantiated by the obser-
vation that TGF-A mRNAs are expressed in mouse embryos
but not in normal adult brain (Wilcox & Derynck, 1988a,b).
In addition, TGF-, has a strong inhibitory effect on mouse
astrocyte proliferation (Sakai et al., 1990). Furthermore, it
has recently been shown that TGF-A1 is involved in
differentiation of O-2Aglial progenitor cells, which give rise
to oligodendrocytes and type 2 astrocytes in the optic nerve
(McKinnon et al., 1993). TGF-,1 was found to inhibit the
mitogenic effect of PDGF, which is responsible for maintain-
ing -2A cells in the proliferative state. In addition, the
identification of a new member of the TGF-P, family, dsl-l,
which isinvolved in the development of neural crest cells
which giverise to Schwann cells, the peripheralglial cells, has
beenreported (Basler et al., 1993). Similarly, our finding that
TGF-P1 is growth inhibitory for the three glioma cell lines
used in this study suggests that this factor may play a role in
modulating the growth ofglial tumours in vivo. It is believed
that TGF-4 is a bifunctional regulator ofcell growth, able to
either stimulate or inhibit proliferation, depending on culture
conditions (Massague, 1990). In this work we have shown
that TGF-4, exhibits a dose-dependent prolonged growth-
inhibitory effect at all the serum concentrations used.
Diffuse infiltrative spread into the normal brain, indepen-
dent of the grade of malignancy, is one of the most impor-
tant features of gliomas in man and constitutes the major
obstacle to successful therapy. The data presented here also
show that migration and invasion do not correlate with the
grade of malignancy of the tumour from which the cell line is
derived, and are well correlated with the behaviour of these
tumours in the patients, therefore supporting the validity of
our in vitro assays. This sytem has proven to be helpful in the
quantitative assessment of human brain tumour invasion
(Albini et al., 1987; Iwasaki et al., 1993). TGF-01 was found
to stimulate migration of the three glioma cell lines. EPRM-5
became motile after TGF-,1 treatment probably as a result of
the induction of expression of ECM proteins, which enable
these cells to attach and migrate. It is well established that
TGF-A1 induces ECM protein production and deposition and
modifies the repertoire of cell-surface adhesion molecules
(Massague, 1990). TGF-P, was also found to be stimulatory
for invasion, with a significant effect on the highly malignant
IPRM-5 cells. This effect is probably due to a modification of
the adhesive properties of the cells. Stimulation of motility
and invasion of glioma cells by TGF-P1 suggests that this
factor may be an important factor in glioma progression and
may play a cruial role in the outcome of the disease. This is,
in fact, strongly supported by very recent data showing that
the presence of TGF-P1 in human gliomas is inversely cor-
related with survival (Mazewski et al., 1993).
It is known that tumorigenesis is accompanied by ana-
plasia. Moreover, glial cells originate from the neuro-
epithelium and are characterised by a high migratory poten-
tial during their development (Shepherd, 1983). One may
therefore speculate that, once transformed, glial cells may
express oncofetal antigens that are normally expressed at the
early stage of their development and which endow them with
the specific mechanisms responsible for the diffuse local
spread observed in gliomas in vivo, and that TGF-P1 could
play a crucial role in this highly motile behaviour. This is
supported by the recent finding that the new TGF-p-related
gene dsl-l promotes migration, during development, of
neural crest cells (Basler et al., 1993) which are characterised
by a motility similar to that of neuroepithelial cells
(Shepherd, 1983). Interestingly, melanocytes also orginate
from the neural crest, and melanomas are characterised by
their high migratory, invasive and metastatic potential
(Cheresh, 1991).
It has been previously reported that TGF-P1 is expressed in
both low- and high-grade malignant gliomas (DeMartin et
al., 1987; Constam et al., 1992; Mazewski et al., 1993). In
addition, these tumours are often accompanied by an
inflammatory reaction at the border between the tumour and
the normal brain structures (Russell & Rubinstein, 1989).
The inflammatory cells include B lymphocytes and macro-
phages, which are known to release TGF-P1 (Sporn &
Roberts, 1988). Therefore, these cells may constitute an addi-
tional important source of TGF-P for glioma cells in vivo,
with which to arrest the proliferation of glioma cells. How-
ever, this action may be detrinental to the normal tissueTGF-P, AND HUMAN GLIOMA CELLS 203
because it favours its infiltration by tumour cells. This is
consistent with the findings of Lindholm et al. (1992), who
suggested that TGF-pl, released from macrophages and
microglial cells, strongly inhibits astroglial proliferation and
controls scar formation after brain injury.
TGF-P, has been considered as a potential therapeutic
factor in many pathological conditions (Sporn & Roberts,
1992). However our data suggest that such therapeutic ap-
plications (particularly in cancer therapy) should take into
account its possible role in migration and invasiveness.
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